๐ ๐๐ซ๐ ๐๐๐ง๐ข๐ฌ๐ฌ๐
- Turnover: โฌ13.41B (previous year โฌ13.74B)
- EBITDA before special items: โฌ4.45B (previous year: โฌ4.09B)
- EBITDA margin before special items: 33.2% (previous year: 29.7%)
- EBIT: โฌ3.53B (previous year โฌ2.32B)
- Net profit: โฌ2.76B (previous year โฌ1.30B)
- Core EPS: โฌ2.71 (previous year โฌ2.40)
- Free cash flow: -โฌ2.32B (previous year: -โฌ1.53B)
- Net financial debt: โฌ32.5B
โ
๐ฏ ๐๐ซ๐จ๐ ๐ง๐จ๐ฌ๐
- Currency-adjusted Group outlook for 2026 confirmed
- Free cash flow 2026 adjusted for legal settlement payments: โฌ2.0-3.0B expected
โ
๐ ๐๐ข๐๐ก๐ญ๐ข๐ ๐ฌ๐ญ๐ ๐๐ฎ๐ง๐ค๐ญ๐๐ญ๐
- Crop Science drives earnings growth through Soybean Seed & Traits and Corn Seed & Traits
- EBITDA before special items increases by 9% despite negative currency effects
- Core EPS increases significantly by 13
- Net profit more than doubled due to higher operating results and special effects
- Free cash flow strongly negative due to payments for legal disputes
- Pharmaceuticals with stable sales but weaker EBITDA
- Consumer Health continues to grow adjusted for currency and portfolio effects
- Net financial debt below previous year's level, but higher than at the end of 2025
โ
๐ฌ ๐๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ-๐๐ฎ๐ฌ๐ฌ๐๐๐ ๐
"We confirm our currency-adjusted Group outlook for 2026."